Innovative Cancer Therapies: Targeting Oncogenic Pathways through Placental Immunology, PROTAC Technology, and Kinase Degradation.

Recent advancements in cancer therapy have led to groundbreaking approaches targeting critical oncogenic pathways. This Patent Highlight explores four essential patents that focus on modulating ligand-receptor interactions from placental immunology, degrading RAF proteins with MEK1/2 degraders, and employing PROTAC technology to degrade Cyclin D, CDK4, and CDK6 proteins. These innovations aim to overcome traditional therapy limitations and address resistance in cancers such as breast, lung, and RAS-altered cancers. This publication examines these inventions' mechanisms, findings, and implications in modern cancer treatment.